{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:27:48Z","timestamp":1744918068070},"reference-count":25,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Punta Toro virus (PTV;\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Bunyaviridae<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Phlebovirus<\/jats:named-content>\n            ) is related to Rift Valley fever virus (RVFV), a pathogenic agent which causes severe disease in humans and livestock primarily in the sub-Saharan region of Africa. The recent range expansion of RVFV and the potential for its intentional release into na\u00efve populations pose a significant threat to public health and agriculture. Studies modeling disease in rodents and nonhuman primates have shown that PTV and RVFV are highly sensitive to the antiviral effects of alpha interferon (IFN-\u03b1), an important component of the innate antiviral host response. While recombinant IFN-\u03b1 has high therapeutic value, its utility for the treatment of neglected tropical diseases is hindered by its short\n            <jats:italic>in vivo<\/jats:italic>\n            half-life and costly production of longer-lasting pegylated IFNs. Here, we demonstrate extended preexposure protection against lethal PTV challenge following a single intranasal administration of DEF201, which is a replication-deficient human adenovirus type 5 vector engineered to constitutively express consensus IFN-\u03b1 (cIFN-\u03b1) from transduced host cells. DEF201 was also efficacious when administered within 24 h as a postexposure countermeasure. Serum concentrations of cIFN-\u03b1 could be detected as early as 8 h following treatment and persisted for more than 1 week. The prolonged antiphlebovirus prophylactic effect, low production costs, and ease of administration make DEF201 a promising agent for intervention during natural disease outbreaks and for countering possible bioterrorist acts.\n          <\/jats:p>","DOI":"10.1128\/aac.00376-12","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T02:55:06Z","timestamp":1337655306000},"page":"4168-4174","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Extended Protection against Phlebovirus Infection Conferred by Recombinant Adenovirus Expressing Consensus Interferon (DEF201)"],"prefix":"10.1128","volume":"56","author":[{"given":"Brian B.","family":"Gowen","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Ennis","sequence":"additional","affiliation":[{"name":"Defyrus Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Sefing","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hui","family":"Wong","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kie-Hoon","family":"Jung","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Turner","sequence":"additional","affiliation":[{"name":"Defyrus Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90207-8"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4269\/ajtmh.2010.09-0289","article-title":"Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies","volume":"83","author":"Anyamba A","year":"2010","unstructured":"AnyambaA. 2010. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am. J. Trop. Med. Hyg. 83:43\u201351.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.234.7.883"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2010.0129","article-title":"Interferon-stimulated genes and their protein products: what and how?","volume":"31","author":"Borden EC","year":"2011","unstructured":"BordenEC WilliamsBR. 2011. Interferon-stimulated genes and their protein products: what and how? J. Interferon Cytokine Res. 31:1\u20134.","journal-title":"J. Interferon Cytokine Res."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0749-0720(02)00029-4","article-title":"Rift Valley fever","volume":"18","author":"Gerdes GH","year":"2002","unstructured":"GerdesGH. 2002. Rift Valley fever. Vet. Clin. North Am. Food Anim. Pract. 18:549\u2013555.","journal-title":"Vet. Clin. North Am. Food Anim. Pract."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2378-2386.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026072"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2008.09.001","article-title":"Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs","volume":"81","author":"Gowen BB","year":"2009","unstructured":"GowenBB. 2009. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res. 81:37\u201346.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.10.002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.antiviral.2007.12.002","article-title":"Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1","volume":"77","author":"Gowen BB","year":"2008","unstructured":"GowenBB WongMH JungKH BlattLM SidwellRW. 2008. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res. 77:215\u2013224.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01635-10"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.11.007"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1099\/0022-1317-77-7-1549","article-title":"Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells","volume":"77","author":"Marshall GS","year":"1996","unstructured":"MarshallGS FengerDP StoutGG KnightsME HuntLA. 1996. Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells. J. Gen. Virol. 77:1549\u20131557.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.Supplement_4.S815"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01311288"},{"key":"e_1_3_2_18_2","unstructured":"NIAID. 2002. Counter-bioterrorism research agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC category A agents. NIAID Bethesda MD."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(86)90024-0"},{"key":"e_1_3_2_20_2","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed LJ","year":"1938","unstructured":"ReedLJ MuenchH. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493\u2013497.","journal-title":"Am. J. Hyg. (Lond.)"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.778-809.2001"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.255"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0166-3542(94)90100-7","article-title":"Antiviral and immunomodulating inhibitors of experimentally induced Punta Toro virus infections","volume":"25","author":"Sidwell RW","year":"1994","unstructured":"SidwellRW. 1994. Antiviral and immunomodulating inhibitors of experimentally induced Punta Toro virus infections. Antiviral Res. 25:105\u2013122.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026330"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.008"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.4172\/2157\u20132526.S1-007"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00376-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00376-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:08:34Z","timestamp":1645481314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00376-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1128\/AAC.00376-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00376-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"2012-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}